New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
07:32 EDTREGN, RHHBYRegeneron may be taking market share from Roche, says Brean Capital
Brean Capital noted Roche (RHHBY) reported Lucentis sales were down from Q4 and believes it is due to Regeneron's (REGN) Eylea taking market share. The firm expects the overall market to remain stable and warns of increased competition later in the year from Avastin. Shares of Regeneron are Buy rated with a $380 price target.
News For REGN;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:49 EDTREGNRegeneron reinstated with a Buy at BofA/Merrill
Subscribe for More Information
September 30, 2014
16:39 EDTRHHBYCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
10:53 EDTREGNRegeneron dupilumab opportunity improved with new data, says Piper Jaffray
Piper Jaffray said it is increasingly optimistic about dupilumab's broad potential in allergic diseases following the Phase II data on chronic sinusitis with nasal polyps as well as prior data in atopic dermatitis and asthma. The firm views dupilumab as a potential blockbuster and reiterates its Overweight rating and $382 price target on Regeneron (REGN), which announced the data in partnership with Sanofi (SNY).
07:30 EDTRHHBYSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
05:16 EDTREGNRegeneron, Sanofi announce positive Phase 2 top-line dupilumab results
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps, or CSwNP, who did not respond to intranasal corticosteroids. In the study, dupilumab resulted in a statistically-significant improvement in the size of nasal polyps, as measured by endoscopic Nasal Polyp Score, the primary endpoint of the study. Statistically significant improvements in all secondary efficacy endpoints were also observed, including objective measures of sinusitis by CT scan, nasal air flow, and patient-reported symptoms. In a pre-specified exploratory analysis, dupilumab-treated patients who also had asthma demonstrated significant improvements in asthma control. The safety profile was consistent with previous studies. The most common AEs with dupilumab were injection site reactions, nasopharyngitis, oropharyngeal pain, epistaxis, headache and dizziness.
September 29, 2014
08:11 EDTRHHBYRoche sees completing InterMune acquisition later today
Subscribe for More Information
07:26 EDTREGNInforma Business Information to hold a conference
Subscribe for More Information
05:35 EDTRHHBYExelixis announces positive results from Phase 3 pivotal trial of cobimetinib
Subscribe for More Information
September 28, 2014
12:49 EDTRHHBYRoche announces final survival results from Phase III CLEOPATRA study
Subscribe for More Information
September 25, 2014
08:59 EDTREGNSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 24, 2014
10:58 EDTRHHBYRoche to host conference call
Conference call to discuss new clinical data on Roche's oncology products and pipeline that were presented at the European Society for Medical Oncology's Annual Meeting will be held on September 29 at 4 am. Webcast Link
September 22, 2014
19:23 EDTRHHBYRoche management to meet with JPMorgan
Subscribe for More Information
13:53 EDTRHHBYRoche launches $5.75B bond to back InterMune acquisition, Reuters reports
Subscribe for More Information
05:17 EDTREGNRegeneron announces EYLEA injection approved for myopic CNV treatment in Japan
Subscribe for More Information
September 20, 2014
15:43 EDTRHHBYInterMune reports MOU in connection with consolidated Delaware action
Subscribe for More Information
September 17, 2014
11:00 EDTRHHBYRoche CEO rules out megadeals, focused on bolt-on acquisitions, WSJ says
Roche CEO Severin Schwan said the company won't change its acquisition strategy following the recent deals made or abandoned in the pharmaceutical sector, reports the Wall Street Journal. In an interview with WSJ, Shwan said, "We have been very consistent in our approach to M&A." Regarding transformational deal-making, he said, "We have no intention to do that, whatever happens in the industry." Reference Link
07:43 EDTRHHBYBofA/Merrill to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use